# Monthly Product Health Report — January 2026

## Executive Summary

This report presents a monthly analysis of product release health using a unified
Product Health Intelligence System. The system integrates multiple data sources,
applies rule-based and machine learning analysis, and uses an LLM to generate
human-readable insights.

Key highlights from this cycle:

- 7 recent releases were evaluated using real post-release signals
- 1 release was flagged as **High Business Risk**
- 2 releases showed **Medium Risk** patterns
- Most releases remained stable with acceptable user feedback
- Correlation analysis was performed using simulated aligned data due to limited
  historical real review coverage

This report is intended to support product, engineering, and operations teams
in identifying post-release risks and prioritizing follow-up actions.

---

## Data Sources

The analysis was performed using the following datasets:

- **Support Tickets (MongoDB)**  
  Customer-reported issues with timestamps and volume trends.

- **App Reviews (MongoDB)**  
  User ratings and review counts collected post-release.

- **Product Releases (CSV / MongoDB)**  
  Versioned release dates used as anchor events for analysis.

- **Simulated Review & Ticket Data**  
  Used only for correlation analysis to demonstrate statistical relationships
  when real historical data volume is insufficient.

All datasets were ingested, cleaned, and processed through a unified ETL pipeline.

---

## Release Health Score Overview

A composite **Release Health Score** was calculated for each release using:

- Ticket change percentage after release
- Average user rating after release
- Review volume normalization

Higher scores indicate healthier releases.

### Summary of Results

- **Top Performing Releases**
  - Version **2025.4** — Health Score: **0.421**
  - Version **2025.7** — Health Score: **0.407**

- **Lowest Performing Release**
  - Version **2025.1** — Health Score: **-0.078**

A negative health score indicates a combination of poor user ratings and
unfavorable support ticket trends relative to other releases.

---

## Anomaly Detection Results (Machine Learning)

An **Isolation Forest** model was applied to identify releases with unusual
post-release behavior based on multiple signals:

- Ticket change percentage
- Average rating
- Review volume
- Composite health score

### High-Risk Releases

- **Version 2025.1**
  - Low average user rating
  - Negative health score
  - Flagged by both ML model and business rules
  - Classified as **High Business Risk**

### Medium-Risk Releases

- Versions **2025.5** and **2025.6**
  - Elevated ticket spikes or weaker rating trends
  - Require monitoring but not immediate action

The anomaly model is unsupervised and does not rely on labeled outcomes.
Validation is performed using business rule alignment and downstream impact signals.

---

## Correlation Analysis (Simulated Data)

Correlation analysis requires multiple releases with aligned ticket and review
signals. Due to limited real historical review data, correlation was computed
using a simulated aligned dataset.

Findings from simulated correlation:

- A moderate negative correlation was observed between ticket increases and
  average user ratings.
- This supports the expected relationship where higher post-release issues
  correlate with lower user satisfaction.

The real-data correlation module is preserved in the pipeline but intentionally
disabled to avoid misleading conclusions.

---

## LLM-Based Anomaly Insights

For releases flagged as anomalous, a Large Language Model (LLM) was used to
generate qualitative explanations based on quantitative signals.

### Example Insight — Version 2025.1

- Likely root cause: Post-release stability or performance degradation
- Primary risk driver: Low user ratings combined with sustained support volume
- Business implication: Increased user dissatisfaction and potential churn risk
- Suggested action: Review recent user feedback and prioritize investigation

The LLM is used strictly for explanation and summarization, not for prediction
or decision-making.

---

## Recommendations & Next Actions

Based on the current analysis, the following actions are recommended:

1. Prioritize investigation of **Version 2025.1** for potential regressions
2. Monitor **Medium Risk** releases for further ticket or rating deterioration
3. Expand review ingestion to increase real-data correlation reliability
4. Automate this pipeline for monthly execution and trend comparison
5. Use anomaly explanations to guide targeted engineering and support actions

---

## Conclusion

This Monthly Product Health Intelligence System demonstrates an end-to-end
internal analytics workflow, combining real-world data ingestion, ETL,
rule-based scoring, machine learning, and LLM-driven explainability.

The system provides actionable insights while explicitly accounting for data
limitations, ensuring that conclusions remain statistically and operationally
sound.
